Unconventional antibody-like and bi-specific derivatives targeting both DR4 and DR5, or DR5 and an antigen specifically expressed by a given tumor cell or tumor microenvironment, have been generated and assessed for their ability to trigger tumor-selective killing. This evidence concerns the gene TNFRSF10A and neoplasm.